At first glance, Jennifer Adams-Tuckers family looks pretty standard- a mom, a dad, two girls, and two boys. However, when three of your four children are diagnosed with autism, your story is anything but standard. And thats the story that Jennifer wants to share with others to prove that individuals with Autism can shine, achieve, inspire and can overcome societal obstacles to accomplish amazing things. Prior to her son, Darryl Jr., being diagnosed with autism, Jennifer was not at all familiar with the condition. I think the only thing I had seen on Autism was a video I had seen a few years ago. The day Darryl Jr. was diagnosed with Autism was scary. I was in this white room with the doctors just telling me he probably wont be able to this, this, and this. It was just all really negative, Adams-Tucker said. She looked to her husband for support. I looked at Darryl with tears in my eyes. Darryl looked up to the doctors and said Thats okay, hes still my boy! These were the words that would carry her through a variety of emotions, but at that point she realized that she and her husband needed to … Continue reading →

Public release date: 26-Sep-2012 [ | E-mail | Share ] Contact: Allison Clair Allison.Clair@nyumc.org 212-404-3753 NYU Langone Medical Center / New York University School of Medicine NYU Langone Medical Center announced today the creation of a new groundbreaking collaboration in autism research. The Autism Brain Imaging Data Exchange (ABIDE) is a database of brain scans from more than 15 leading international research institutions and academic medical centers. ABIDE was designed to advance scientific understanding of Autism Spectrum Disorder (ASD) by allowing researchers to share autism data within the broader scientific community. The collaboration is led by NYU Langone, coordinator of ABIDE and the single largest contributor of research to the consortium, and Kennedy Krieger Institute. "This collaboration fills an unmet need among the autism research community. By providing access to an unprecedented large-scale dataset, ABIDE has the potential to move autism research forward and thus advance our understanding of a complex disorder," said Adriana Di Martino, MD, co-founder and coordinator of ABIDE and Leon Levy assistant professor of child and adolescent psychiatry at the Child Study Center at NYU Langone Medical Center. "We are honored that some of the world's leading institutions have contributed data and truly feel this initiative … Continue reading →

TUESDAY, Sept. 25 (HealthDay News) -- Many children with autism have interrelated health problems that can have a significant impact on their home and school lives, a new study finds. Researchers looked at nearly 3,000 children with autism and found that nearly one-fourth also had chronic gastrointestinal problems such as constipation, abdominal pain, bloating, diarrhea and nausea. The children with the chronic gastrointestinal problems also had anxiety and so-called "atypical sensory responses," which are heightened reactions to light, sound or particular textures, according to the study, which was published recently in the Journal of Abnormal Child Psychology. "These problems can have a very real impact on daily life. Children with anxiety may be distressed or reluctant to engage in new activities, and those with sensory problems may have trouble paying attention or participating in overstimulating environments," Micah Mazurek, assistant professor of health psychology and a clinical child psychologist at the University of Missouri, said in a university news release. "These children may also suffer uncomfortable [gastrointestinal] problems that they may not be able to communicate about to adults." Effective management of these problems may improve autistic children's quality of life and response to treatment, she said. "Parents need to be … Continue reading →

Updated: September 26, 2012, 12:47 AM ET CINCINNATI -- Reds manager Dusty Baker had a stroke in addition to his irregular heartbeat last week and will need another week of rest before he's able to rejoin the team for the final regular-season series and the playoffs. The 63-year-old manager disclosed his condition to his players on Tuesday before the start of a series against the Milwaukee Brewers. Bench coach Chris Speier and players said Baker was upbeat and visibly thinner. "He's lost a lot of water weight," Speier said. "He was anxious [to get back]. It was great to see him. Again, he looks really, really good. We're all anxious to get him back in charge." Speier will manage the three-game series against the Brewers and a three-game series in Pittsburgh over the weekend. Baker could return for the final three games in St. Louis starting Monday, followed by the playoffs. The Reds clinched their second NL Central title in the last three years while Baker was still in a Chicago hospital on Saturday night. "I'm feeling much better, and it's great being back here in Cincinnati," Baker said, in a statement released after he met with owner Bob Castellini … Continue reading →

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company(BMY) and Pfizer Inc. (PFE) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission for ELIQUIS (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). The FDA assigned a new Prescription Drug User Fee Act (PDUFA) goal date of March 17, 2013. The FDA has deemed the resubmission a complete response to its June 22, 2012 Complete Response Letter that requested additional information on data management and verification from the ARISTOTLE trial. The ELIQUIS NDA is based on the results of the ARISTOTLE and AVERROES studies. These clinical studies evaluated ELIQUIS in approximately 24,000 patients with NVAF, in the largest clinical trial program conducted to date in this patient population. The landmark ARISTOTLE trial compared apixaban to warfarin, the standard of care, in more than 18,000 NVAF patients, while AVERROES compared apixaban to aspirin in 5,598 NVAF patients who were unsuitable for vitamin K antagonist (VKA) therapy. ARISTOTLE and AVERROES are part of an ongoing clinical development program for ELIQUIS, which is projected to include nearly 60,000 patients worldwide across multiple indications and … Continue reading →